1
|
Ippolito E, Di Donato A, Marrocco M, Floreno B, Giannetti F, D’Auria G, Gamucci T, Ramella S. PO-1870 PRETREATMENT SELECTION FOR LAD SPARING IN PERSONALIZED BREATH HOLD BREAST RADIOTHERAPY. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08321-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Krasniqi E, Sacconi A, Marinelli D, Pizzuti L, Mazzotta M, Sergi D, Capomolla E, Donzelli S, Carosi M, Bagnato A, Gamucci T, Tomao S, Natoli C, Marchetti P, Grassadonia A, Tinari N, De Tursi M, Vizza E, Ciliberto G, Landi L, Cappuzzo F, Barba M, Blandino G, Vici P. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study. Biomark Res 2021; 9:57. [PMID: 34256855 PMCID: PMC8276429 DOI: 10.1186/s40364-021-00289-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 04/26/2021] [Indexed: 02/06/2023] Open
Abstract
Background In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable gains in therapeutical options. Novel biomarkers of early diagnosis, prognosis definition and prediction of treatment outcomes are of pivotal importance. Prior studies have shown the potentials of micro-ribonucleic acids (miRNAs) as biomarkers for OC and other cancers. Methods We focused on the prognostic and/or predictive potential of miRNAs in OC by conducting a comprehensive array profiling of miRNA expression levels in ovarian tissue samples from 17 non-neoplastic controls, and 60 tumor samples from OC patients treated at the Regina Elena National Cancer Institute (IRE). A set of 54 miRNAs with differential expression in tumor versus normal samples (T/N-deregulated) was identified in the IRE cohort and validated against data from the Cancer Genoma Atlas (TCGA) related to 563 OC patients and 8 non-neoplastic controls. The prognostic/predictive role of the selected 54 biomarkers was tested in reference to survival endpoints and platinum resistance (P-res). Results In the IRE cohort, downregulation of the 2 miRNA-signature including miR-99a-5p and miR-320a held a negative prognostic relevance, while upregulation of miR-224-5p was predictive of less favorable event free survival (EFS) and P-res. Data from the TCGA showed that downregulation of 5 miRNAs, i.e., miR-150, miR-30d, miR-342, miR-424, and miR-502, was associated with more favorable EFS and overall survival outcomes, while miR-200a upregulation was predictive of P-res. The 9 miRNAs globally identified were all included into a single biologic signature, which was tested in enrichment analysis using predicted/validated miRNA target genes, followed by network representation of the miRNA-mRNA interactions. Conclusions Specific dysregulated microRNA sets in tumor tissue showed predictive/prognostic value in OC, and resulted in a promising biological signature for this disease. Supplementary Information The online version contains supplementary material available at 10.1186/s40364-021-00289-6.
Collapse
Affiliation(s)
- E Krasniqi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - A Sacconi
- UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - D Marinelli
- Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Medical Oncology Unit, Sapienza University, Via di Grottarossa 1035/1039, 00189, Rome, Italy
| | - L Pizzuti
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - M Mazzotta
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - D Sergi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - E Capomolla
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - S Donzelli
- Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - M Carosi
- Pathology Department IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - A Bagnato
- Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - T Gamucci
- Medical Oncology, Sandro Pertini Hospital, Via dei Monti Tiburtini 385, 00157, Rome, Italy
| | - S Tomao
- Department of Radiological Oncological and Pathological Sciences, Division of Medical Oncology A, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy
| | - C Natoli
- Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Via dei Vestini, 31, 66100, Chieti, Italy
| | - P Marchetti
- Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Medical Oncology Unit, Sapienza University, Via di Grottarossa 1035/1039, 00189, Rome, Italy
| | - A Grassadonia
- Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Via dei Vestini, 31, 66100, Chieti, Italy
| | - N Tinari
- Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Via dei Vestini, 31, 66100, Chieti, Italy
| | - M De Tursi
- Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Via dei Vestini, 31, 66100, Chieti, Italy
| | - E Vizza
- Department of Oncological Surgery, Gynecologic Oncologic Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - G Ciliberto
- Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - L Landi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - F Cappuzzo
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - M Barba
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - G Blandino
- Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - P Vici
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| |
Collapse
|
3
|
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Caputo R, Cianniello D, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]. ESMO Open 2021; 6:100097. [PMID: 33926709 PMCID: PMC8103531 DOI: 10.1016/j.esmoop.2021.100097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Affiliation(s)
- C De Angelis
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - D Bruzzese
- Department of Public Health, University of Naples "Federico II", Naples, Italy
| | - A Bernardo
- Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy
| | - E Baldini
- Department of Oncology, S. Luca Hospital, Lucca, Italy
| | - L Leo
- Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy
| | - A Fabi
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - T Gamucci
- Medical Oncology Unit, ASL Frosinone, Frosinone, Italy
| | - P De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - F Poggio
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - S Russo
- Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Lauria
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - I De Santo
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Caputo
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - D Cianniello
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - A Michelotti
- Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy
| | - L Del Mastro
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy
| | - M De Laurentiis
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| |
Collapse
|
4
|
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6:100054. [PMID: 33601296 PMCID: PMC7900694 DOI: 10.1016/j.esmoop.2021.100054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/03/2021] [Accepted: 01/12/2021] [Indexed: 12/12/2022] Open
Abstract
Background We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab. Patients and methods This is a multicenter, single-arm, Simon's two-stage, phase II study. The primary endpoint was the overall response rate, considered as the sum of partial and complete response based on the best overall response rate (BORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), and clinical benefit rate. Results A total of 58 of the 61 patients enrolled in the study were evaluable for efficacy. The BORR was 24.6% (95% CI 14.5-37.3). The clinical benefit rate was 32.8% (95% CI 21.3-46.0). The median PFS was 6.2 months (95% CI 4.0-7.8), and median OS was 14.8 months (95% CI 12.6-22.8). Overall, adverse events (AEs) were clinically manageable and the most common AEs were fatigue, paresthesia, and neutropenia. Quality of life was well preserved in most patients. Conclusions The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC. Bevacizumab + chemotherapy improved progression-free survival in HER2-negative metastatic breast cancer (MBC) patients. Eribulin monotherapy improved overall survival in patients with anthracycline- and taxane-pretreated MBC. The GIM11-BERGI trial assessed the efficacy and safety of eribulin + bevacizumab as second-line treatment for HER2-MBC. Eribulin + bevacizumab showed to be a safe and active treatment after progression to first-line paclitaxel + bevacizumab.
Collapse
Affiliation(s)
- C De Angelis
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - D Bruzzese
- Department of Public Health, University of Naples "Federico II", Naples, Italy
| | - A Bernardo
- Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy
| | - E Baldini
- Department of Oncology, S. Luca Hospital, Lucca, Italy
| | - L Leo
- Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy
| | - A Fabi
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - T Gamucci
- Medical Oncology Unit, ASL Frosinone, Frosinone, Italy
| | - P De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - F Poggio
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - S Russo
- Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Lauria
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - I De Santo
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - A Michelotti
- Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy
| | - L Del Mastro
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy
| | - M De Laurentiis
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| |
Collapse
|
5
|
Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, Sanguineti G, Massimiani G, Sergi D, Carpano S, Marchetti P, Tomao S, Gamucci T, De Maria R, Tomao F, Natoli C, Tinari N, Ciliberto G, Barba M, Vici P. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol 2019; 12:111. [PMID: 31665051 PMCID: PMC6820969 DOI: 10.1186/s13045-019-0798-2] [Citation(s) in RCA: 81] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 09/25/2019] [Indexed: 02/08/2023] Open
Abstract
Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The immune system holds the ability to spontaneously implement a defensive response against HER2+ BC cells through complex mechanisms which can be exploited to modulate this response for obtaining a clinical benefit. Initial immune system modulating strategies consisted mostly in vaccine therapies, which are still being investigated and improved. However, the entrance of trastuzumab into the scenery of HER2+ BC treatment was the real game changing event, which embodied a dominant immune-mediated mechanism. More recently, the advent of the immune checkpoint inhibitors has caused a new paradigm shift for immuno-oncology, with promising initial results also for HER2+ BC. Breast cancer has been traditionally considered poorly immunogenic, being characterized by relatively low tumor mutation burden (TMB). Nevertheless, recent evidence has revealed high tumor infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in a considerable proportion of HER2+ BC patients. This may translate into a higher potential to elicit anti-cancer response and, therefore, wider possibilities for the use and implementation of immunotherapy in this subset of BC patients. We are herein presenting and critically discussing the most representative evidence concerning immunotherapy in HER2+ BC cancer, both singularly and in combination with therapeutic agents acting throughout HER2-block, immune checkpoint inhibition and anti-cancer vaccines. The reader will be also provided with hints concerning potential future projection of the most promising immutherapeutic agents and approaches for the disease of interest.
Collapse
Affiliation(s)
- E Krasniqi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - G Barchiesi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - L Pizzuti
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - M Mazzotta
- Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, Italy
| | - A Venuti
- HPV-UNIT, UOSD Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostic and Technological Innovation (RIDAIT), Translational Research Functional Departmental Area, IRCSS Regina Elena National Cancer Institute, Rome, Italy
| | - M Maugeri-Saccà
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - G Sanguineti
- Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - G Massimiani
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - D Sergi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - S Carpano
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| | - P Marchetti
- Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, Italy.,Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy
| | - S Tomao
- Department of Radiological, Oncological and Anatomo-Pathological Sciences, Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy
| | - T Gamucci
- Medical Oncology, Sandro Pertini Hospital, Rome, Italy
| | - R De Maria
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy.,Department of Medical Oncology, Policlinico Universitario "A. Gemelli", Rome, Italy
| | - F Tomao
- Department of Gynecology-Obstetrics and Urology, "Sapienza" University of Rome, Rome, Italy
| | - C Natoli
- Department of Medical, Oral and Biotechnological Sciences and Center of Aging Science & Translational Medicine (CeSI-MeT), G. d'Annunzio University, Chieti, Italy
| | - N Tinari
- Department of Medical, Oral and Biotechnological Sciences and Center of Aging Science & Translational Medicine (CeSI-MeT), G. d'Annunzio University, Chieti, Italy
| | - G Ciliberto
- Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - M Barba
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy.
| | - P Vici
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53-00144, Rome, Italy
| |
Collapse
|
6
|
Conte B, Bruzzone M, Lambertini M, Poggio F, Blondeaux E, De Laurentiis M, Valle E, Cognetti F, Nisticò C, De Placido S, Merlano M, Gamucci T, Montemurro F, Ceppi M, Del Mastro L. Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-21-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: At present, there is no standard second-line chemotherapy-based treatment in patients with HER2-negative MBC. Continued VEGF inhibition with bevacizumab is a new potential option in patients progressing to first line bevacizumab and chemotherapy. Eribulin is a non-taxane microtubule dynamics inhibitor, with a unique mechanism of action and suggested beneficial effects on tumor microenvironment and neoangiogenesis. This study evaluated efficacy and safety of eribulin plus bevacizumab as a novel second-line chemotherapy scheme, in patients progressing after first line paclitaxel and bevacizumab.
Methods: This is a multicenter, single-arm, Simon's two-stage, Phase II study. Patients with HER2-negative MBC progressing to paclitaxel and bevacizumab received eribulin (1.23 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle) plus bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks intravenously), as second-line chemotherapy. The primary endpoint was the overall response rate (ORR), considered as sum of partial (PR) and complete response (CR), basing on the best overall response. The present safety and efficacy analyses, as planned per study design, refer to six cycles of treatment (18 weeks).
Results: Among the 61 patients enrolled in the study, 55 (90,2% ) were evaluable for efficacy. ORR (PR/CR) was 9.1% [95% confidence intervals (C.I.) 3.0 to 19.9]; stable disease (SD) rate was 63.6% [95% C.I. 49.6 to 76.2]; clinical benefit rate (CR/PR/SD) at 24 weeks was 35% [95% C.I. 22.0 to 49.1]. The median progression free survival was 6.3 months [95% C.I. 4.1 to 7.8 months]. Drugs-related adverse events (AEs) were: 49.5% related to eribulin, 7.7% related to bevacizumab, and 11.8% related to both the study drugs. The most common AEs were fatigue (9.9% of all AEs), paresthesia (6.5% of all AEs) and neutropenia (6.2% of all AEs). Quality of life was well preserved among the majority of patients.
Conclusions: The results of our trial suggest that continuing bevacizumab in combination with eribulin, beyond first line treatment with bevacizumab and paclitaxel, offers a reasonable therapeutic option for patients with HER2-negative MBC, without detrimentally affecting quality of life.
Citation Format: De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-13.
Collapse
Affiliation(s)
- S De Placido
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - M De Laurentiis
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - D Bruzzese
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - A Bernardo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - EE Baldini
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - V Montesarchio
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - A Fabi
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - T Gamucci
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - P De Placido
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - S Russo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - R Lauria
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - I De Santo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - C De Angelis
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - L Del Mastro
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - M Giuliano
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - G Arpino
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| |
Collapse
|
8
|
Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, Verusio C, Lionetto R, Dani C, Casali P, Santoro A. Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. Tumori 2018; 85:229-33. [PMID: 10587022 DOI: 10.1177/030089169908500403] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose To evaluate the maximum tolerated doses (MTD) of ifosfamide when given as a continuous infusion and in combination with fixed doses of bolus 4′-epidoxorubicin in advanced previously untreated adult soft tissue sarcoma patients. Methods Treatment consisted of epidoxorubicin, 60 mg/m2 days one and two, and ifosfamide, 1.5 g/m2 every 12 hrs as a 72-hr infusion, at the first level. Further levels of ifosfamide were defined as increments of 12 hrs of the same infusion program. G-CSF 300 μg/die was administered from days +7 to +14. Dose-limiting toxicity (DLT) was defined as: G4 leukopenia or thrombocytopenia of ≥5 days; any G3 neuro or nephrotoxicity; G4 toxicity of any kind. Patients had to complete at least 2 consecutive cycles, and MTD was defined as the level in which 20% of patients developed a DLT; 10-15 patients were entered in each level. Results First level: overall, 13 patients entered, 3 were not assessable for MTD, and only one developed a DLT. Second level: 18 patients entered, 3 were not assessable for MTD. Hematologic DLT was observed in 3/15 assessable patients. Therefore, the MTD was found at the ifosfamide level of 10.5 g/m2 given in 84 hrs. Eight patients of 29 assessable for response achieved an objective response: 1 complete and 7 partial. The overall response rate was 28% (95% CI: 13-47%). Conclusions If we accept 4-day G4 leukopenia as a reliable cutoff for safety, ifosfamide intensification cannot be substantially exploited over already available schedules with the combination of ifosfamide and anthracyclines.
Collapse
Affiliation(s)
- S Frustaci
- Divisione di Oncologia Medica, Centro di Riferimento Oncologico, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
A case is reported of cardiotoxicity during a multiple drug treatment with fluorouracil, vincristine and CCNU in a patient with a large bowel cancer without any precedent history of heart disease. The patient had chest pain, with an altered ECG and increased serum levels of αHBDH.
Collapse
|
10
|
Garassino M, Cortesi E, Grossi F, Chiari R, Parra HS, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pinto C, Galetta D, Macerelli M, De Marinis F. MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.550] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Mentuccia L, Gelibter A, Sperduti I, D'Onofrio L, Botticelli A, Vici P, Cassano A, Moscetti L, Carbognin L, Graziano V, Barchiesi G, Rossi E, Cursano M, Pizzuti L, Paris I, Vaccaro A, Fabbri A, Rossi L, Samaritani R, Sarmiento R, Gamucci T. Efficacy of pertuzumab in combination with trastuzumab and a taxane in in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Puglisi F, Ceppi M, Gerratana L, Cognetti F, De Placido S, Bruzzi P, De Laurentiis M, Bisagni G, Cavazzini G, Durando A, Turletti A, Valle E, Montemurro F, Barni S, Ardizzoni A, Colantuoni G, Gamucci T, Del Mastro L. Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Garassino M, Cortesi E, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pagano M, Macerelli M, Lagroscino A, De Marinis F. Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Puglisi F, Ceppi M, Cognetti F, De Placido S, Bruzzi P, De Laurentiis M, Bisagni G, Cavazzini G, Durando A, Turletti A, Valle E, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Del Mastro L. Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background In patients with node-positive early breast cancer (EBC), dose-dense adjuvant chemotherapy improves disease-free survival (DFS) compared with standard interval chemotherapy. The GIM2 trial supports the value of dose-dense chemotherapy and suggests that the benefit is present in patients with hormone receptor-negative or hormone receptor-positive tumours (Del Mastro et al. Lancet 2015). In order to individualize decision making, there is a need to examine the absolute treatment effects of dose dense chemotherapy according to patient and tumor characteristics.
Patients and Methods The randomized phase III GIM2 trial enrolled 2091 patients. The primary endpoint was DFS. A continuous, composite measure of treatment benefit for each patient was determined from a Cox model incorporating potential predictive factors (age: 25-40/41-55/56-71; histological grade: 1+2/3; hormonal receptor status: positive/negative). Subpopulation treatment effect pattern plot methodology was used to reveal differential treatment effects on DFS according to composite index. The study focused on patients with HER2–negative disease (N=1287).
Results On average, the magnitude of benefit with dose dense chemotherapy versus standard chemotherapy ranged widely across different subpopulations, as quantified by the composite measure of relevant variables. The highest benefit was observed in patients with high grade, hormone receptor-negative disease (hazard ratio for DFS 0.44, 95% CI 0.23-0.83). Of note, a relevant benefit was observed also in patients with high grade, hormone receptor-positive disease (hazard ratio for DFS 0.74, 95% CI 0.50-1.09).
Conclusion The absolute improvement in DFS with dose dense adjuvant chemotherapy is substantial in some patients with node-positive HER2-negative breast cancer, particularly those regarded as having high index risk (hormone receptor-negative, high grade disease). Interestingly, a significant effect of dose dense chemotherapy was observed also in patients with hormone receptor-positive, high grade disease.
Citation Format: Puglisi F, Ceppi M, Cognetti F, De Placido S, Bruzzi P, De Laurentiis M, Bisagni G, Cavazzini G, Durando A, Turletti A, Valle E, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Del Mastro L. Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-12.
Collapse
Affiliation(s)
- F Puglisi
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - M Ceppi
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - F Cognetti
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - S De Placido
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - P Bruzzi
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - M De Laurentiis
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - G Bisagni
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - G Cavazzini
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - A Durando
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - A Turletti
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - E Valle
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - F Montemurro
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - S Barni
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - A Ardizzoni
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - T Gamucci
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - G Colantuoni
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - L Del Mastro
- University Hospital of Udine, Udine, Italy; Gruppo Italiano Mammella, Italy; IRCCS AOU San Martino–IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| |
Collapse
|
15
|
Moscetti L, Fabbri M, Vici P, Natoli C, Gamucci T, Sperduti I, Pizzuti L, Iezzi L, Iattoni E, Roma C, Vaccaro A, D'Auria G, Mauri M, Ruggeri E. Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients. The Ful500 prospective observational trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
16
|
Pizzuti L, Sperduti I, Michelotti A, Omarini C, Gamucci T, Natoli C, D'Onofrio L, Giotta F, Ficorella C, Laudadio L, Cassano A, Marchetti P, Adamo V, Mauri M, Scinto A, Zampa G, Fabbri A, Mentuccia L, Barni S, Vici P. Trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC): Results from a multicenter retrospective analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Pizzuti L, Sperduti I, Michelotti A, Omarini C, Gamucci T, Natoli C, D'Onofrio L, Giotta F, Ficorella C, Laudadio L, Cassano A, Marchetti P, Adamo V, Mauri M, Scinto A, Zampa G, Fabbri A, Mentuccia L, Barni S, Vici P. Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Moscetti L, Fabbri M, Vici P, Natoli C, Gamucci T, Sperduti I, Pizzuti L, Iezzi L, Iattoni E, Roma C, Vaccaro A, D'Auria G, Mauri M, Ruggeri E. Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Quadrini S, Sperduti I, Narducci F, Ciancola F, Mastroianni D, Mauri M, Fabbri A, Ruggieri E, Roma C, Mansueto G, Gamucci T. Observational prospective study to evaluate survival, quality of life and cost of oncologic treatments for advanced non small cell lung cancer (NSCLC) patients that progressed after a first line of treatment: preliminary analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Fabbri M, Sternberg C, Cortesi E, Santini D, Procopio G, Paolo M, Gamucci T, Carlini P, Roselli M, Longo F, Schinzari G, De Tursi M, Lanzetta G, Pellegrino A, Milano A, Sperduti I, Mancini M, Primi F, Ruggeri E. A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Zilembo N, Giannetta L, Crinò L, Bearz A, Amoroso D, Gamucci T, Buscaglia M, Tiseo M, Soldatenkova V, Chouaki N, Depenbrock H, Hirsch F, Paz-Ares L, Bidoli P. SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Fontanella C, Del Mastro L, De Placido S, De Laurentiis M, Boni C, Giovanna C, Durando A, Turletti A, Turletti A, Nisticò C, Valle E, Garrone O, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Bighin C, Cognetti F, Puglisi F. The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines 2016; 15:1327-36. [PMID: 27063030 PMCID: PMC5152541 DOI: 10.1080/14760584.2016.1176533] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.
Collapse
Affiliation(s)
- P Vici
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - L Pizzuti
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - L Mariani
- b HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.,c Department of Gynecologic Oncology , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - G Zampa
- d Oncology Unit , Nuovo Regina Margherita Hospital , Rome , Italy
| | - D Santini
- e Department of Medical Oncology , University Campus Bio-Medico , Rome , Italy
| | - L Di Lauro
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - T Gamucci
- f Medical Oncology Unit, ASL Frosinone , Frosinone , Italy
| | - C Natoli
- g Department of Medical, Oral and Biotechnological Sciences, Experimental and Clinical Sciences , University 'G. d'Annunzio' , Chieti , Italy
| | - P Marchetti
- h Oncology Unit, Sant'Andrea Hospital , 'Sapienza' University of Rome , Rome , Italy
| | - M Barba
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.,i Scientific Direction , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - M Maugeri-Saccà
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.,i Scientific Direction , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - D Sergi
- a Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - F Tomao
- j Department of Gynecologic and Obstetric Sciences , La Sapienza University of Rome , Rome , Italy
| | - E Vizza
- b HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - S Di Filippo
- k Emergency Department , Santa Maria Goretti Hospital , Latina , Italy
| | - F Paolini
- b HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - G Curzio
- b HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - G Corrado
- c Department of Gynecologic Oncology , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - A Michelotti
- l Oncology Unit I , Azienda Ospedaliera Universitaria Pisana , Pisa , Italy
| | - G Sanguineti
- m Radiotherapy , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - A Giordano
- n Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology , Temple University , Philadelphia , PA , USA.,o Department of Human Pathology and Oncology , University of Siena , Siena , Italy
| | - R De Maria
- i Scientific Direction , 'Regina Elena' National Cancer Institute , Rome , Italy
| | - A Venuti
- b HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy
| |
Collapse
|
24
|
Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, Caraceni A, Kaasa S, Dragani TA, Azzarello G, Luzzani M, Cavanna L, Bandieri E, Gamucci T, Lipari G, Di Gregorio R, Valenti D, Reale C, Pavesi L, Iorno V, Crispino C, Pacchioni M, Apolone G. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Ann Oncol 2016; 27:1107-1115. [PMID: 26940689 DOI: 10.1093/annonc/mdw097] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2015] [Accepted: 02/16/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Guidelines tend to consider morphine and morphine-like opioids comparable and interchangeable in the treatment of chronic cancer pain, but individual responses can vary. This study compared the analgesic efficacy, changes of therapy and safety profile over time of four strong opioids given for cancer pain. PATIENT AND METHODS In this four-arm multicenter, randomized, comparative, of superiority, phase IV trial, oncological patients with moderate to severe pain requiring WHO step III opioids were randomly assigned to receive oral morphine or oxycodone or transdermal fentanyl or buprenorphine for 28 days. At each visit, pain intensity, modifications of therapy and adverse drug reactions (ADRs) were recorded. The primary efficacy end point was the proportion of nonresponders, meaning patients with worse or unchanged average pain intensity (API) between the first and last visit, measured on a 0-10 numerical rating scale. (NCT01809106). RESULTS Forty-four centers participated in the trial and recruited 520 patients. Worst pain intensity and API decreased over 4 weeks with no significant differences between drugs. Nonresponders ranged from 11.5% (morphine) to 14.4% (buprenorphine). Appreciable changes were made in the treatment schedules over time. Each group required increases in the daily dose, from 32.7% (morphine) to 121.2% (transdermal fentanyl). Patients requiring adjuvant analgesics ranged from 68.9% (morphine) to 81.6% (oxycodone), switches varied from 22.1% (morphine) to 12% (oxycodone), discontinuation of treatment from 27% ( morphine) to 14.5% (fentanyl). ADRs were similar except for effects on the nervous system, which significantly prevailed with morphine. CONCLUSION The main findings were the similarity in pain control, response rates and main adverse reactions among opioids. Changes in therapy schedules were notable over time. A considerable proportion of patients were nonresponders or poor responders. CLINICAL TRIAL REGISTRATION NCT01809106 (https://clinicaltrials.gov/ct2/show/NCT01809106?term=cerp&rank=2).
Collapse
Affiliation(s)
- O Corli
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative.
| | - I Floriani
- Department of Oncology, Laboratorio di Ricerca Clinica, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan
| | - A Roberto
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative
| | - M Montanari
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative
| | - F Galli
- Department of Oncology, Laboratorio di Ricerca Clinica, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan
| | - M T Greco
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative; Department of Statistics, Università di Milano, Milan
| | - A Caraceni
- Palliative Care Complex Structure, Terapia del dolore e Riabilitazione, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Kaasa
- Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Norway
| | - T A Dragani
- S.S.D. Epidemiology, Genetics and Pharmacogenomics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - G Azzarello
- Department of Hematology and Oncology, Ospedale di U.O.C. di Oncologia Mirano-ASL 13 Regione Veneto, Mirano
| | - M Luzzani
- Department of Orthogeriatrics, S.S.D. Cure Palliative, riabilitazione e stabilizzazione E.O. Ospedali Galliera, Genova
| | - L Cavanna
- Oncology Unit, Ospedale di Piacenza, Piacenza
| | - E Bandieri
- Unit of Supportive and Simultaneous Care, Medical Oncology Division USL, Modena
| | - T Gamucci
- UOC Medical Oncology, Ospedale SS Trinità, Sora
| | - G Lipari
- Palliative Care, P.O. di Salemi-ASP 9, Trapani
| | - R Di Gregorio
- U.O.S Obstetric Anasthesia and Pain Therapy, Opedale Sacro Cuore di Gesù - Fatebenefratelli, Benevento
| | - D Valenti
- Palliative Care Unit, Azienda Ospedaliera Valtellina e Valchiavenna, Morbegno
| | - C Reale
- Department of Cardiovascular Sciences, Respiratory, Nephrological, Anaesthetics and Geriatrics, Policlinico Universitario Umberto I, Rome
| | - L Pavesi
- Unit of Oncology, RCCS-Fondazione Salvatore Maugeri, Pavia
| | - V Iorno
- Centre for Pain Medicine M. TIENGO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
| | - C Crispino
- UOSD Treatment of Lung Cancer Complications, AO Dei Colli Monaldi Cotugno CTO Ospedale Monaldi, Napoli
| | - M Pacchioni
- Department of Oncology, Ospedale San Raffaele IRCCS, Milan
| | - G Apolone
- Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | |
Collapse
|
25
|
Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol 2015; 27:487-93. [PMID: 26681678 DOI: 10.1093/annonc/mdv608] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 12/09/2015] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Current evidence suggest that trabectedin is particularly effective in cells lacking functional homologous recombination repair mechanisms. A prospective phase II trial was designed to evaluate the activity of trabectedin in the treatment of recurrent ovarian cancer patients presenting BRCA mutation and/or BRCAness phenotype. PATIENTS AND METHODS A total of 100 patients with recurrent BRCA-mutated ovarian cancer and/or BRCAness phenotype (≥2 previous responses to platinum) were treated with trabectedin 1.3 mg/mq i.v. q 3 weeks. The activity of the drug with respect to BRCA mutational status and to a series of polymorphisms [single-nucleotide polymorphisms (SNPs)] involved in DNA gene repair was analyzed. RESULTS Ninety-four were evaluable for response; in the whole population, 4 complete and 33 partial responses were registered for an overall response rate (ORR) of 39.4. In the platinum-resistant (PR) and -sensitive (PS) population, an ORR of 31.2% and 47.8%, and an overall clinical benefit of 54.2% and 73.9%, respectively, were registered. In the whole series, the median progression-free survival (PFS) was 18 weeks and the median overall survival (OS) was 72 weeks; PS patients showed a more favorable PFS and OS compared with PR patients. BRCA gene mutational status was available in 69 patients. There was no difference in ORR, PFS and OS according to BRCA 1-2 status nor any association between SNPs of genes involved in DNA repair and NER machinery and response to trabectedin was reported. CONCLUSIONS Our data prospectively confirmed that the signature of 'repeated platinum sensitivity' identifies patients highly responsive to trabectedin. In this setting, the activity of trabectedin seems comparable to what could be obtained using platinum compounds and the drug may represent a valuable alternative option in patients who present contraindication to receive platinum. EUDRACT NUMBER 2011-001298-17.
Collapse
Affiliation(s)
- D Lorusso
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - G Scambia
- Department of Obstetrics and Gynecology, Catholic University of Rome
| | - S Pignata
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - R Sorio
- Department of Oncology, CRO Aviano, Aviano
| | - G Amadio
- Department of Obstetrics and Gynecology, Catholic University of Rome
| | - S Lepori
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - A Mosconi
- Medical Oncology Unit, University Hospital S. Maria della Misericordia, Perugia
| | - C Pisano
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - G Mangili
- Department of Obstetrics and Gynecology, San Raffaele Hospital, Milan
| | - G Maltese
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - R Sabbatini
- Department of Oncology Haematology and Respiratory Disease, AOU Policlinico di Modena, Modena
| | - G Artioli
- Medical Oncology Unit, Hospital of Mirano, Mirano
| | - T Gamucci
- Medical Oncology Unit, Hospital 'SS. Trinità', Sora
| | - M Di Napoli
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - E Capoluongo
- Department of Molecular Biology, Catholic University of Rome
| | - V Ludovini
- Molecular Biology Unit, University Hospital S. Maria della Misericordia, Perugia, Italy
| | - F Raspagliesi
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - G Ferrandina
- Department of Obstetrics and Gynecology, Catholic University of Rome
| |
Collapse
|
26
|
Iezzi L, Mentuccia L, Vici P, Natoli C, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Magnolfi E, Sergi D, Gamucci T. Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: a restrospective multicenter observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli M, Pastorino S, Pronzato P, Del Mastro L. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv335.01] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Pizzuti L, Barba M, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Fancelli S, Grassadonia A, Michelotti A, Pescarmona E, Perracchio L, Maugeri-Saccà M, Vici P. Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Mentuccia L, Fabi A, Cassano A, Vici P, Michelotti A, Sperduti I, Sarobba G, Marchetti P, Scognamiglio M, Vaccaro A, Rossi E, Pellegrini D, Nicoletta D, Pellegrino A, Sini V, Pizzuti L, Palleschi M, Moscetti L, Jamara G, Ciancola F, Gamucci T. Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Scelzi E, Bernardi D, Bonciarelli G, Salesi N, Frassoldati A, Maisano R, Tagliaferri P, Gamucci T, Mencoboni M, Raggi T, Rosti G. Biosimilar epoetin alfa in the management of chemotherapy-induced aneamia: results from ANEMONE observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Fabbri M, Cortesi E, Marchetti P, Santini D, Gamucci T, Angelini F, Longo F, Milano A, Mancini M, Giuli A, Quadrini S, Sperduti I, Pellegrino A, Ratta R, Primi F, Chilelli M, Ruggeri E. 2544 Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31363-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Gamucci T, Mentuccia L, Vici P, Iezzi L, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Sergi D, Magnolfi E, Natoli C. 1950 Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30898-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Pizzuti L, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Mentuccia L, Vaccaro A, Trenta P, Seminara P, Rapposelli I, Sini V, Santini D, Sperduti I, Marchetti P, Vici P. Her2-Positive Early Breast Cancer in the Pre-Trastuzumab and Trastuzumab Eras: a Triple Positive Subgroup Analysis of a Multicenter Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Salvatore L, Cremolini C, Loupakis F, Masi G, Schirripa M, Marmorino F, Bergamo F, Zagonel V, Aprile G, Allegrini G, Tonini G, Zaniboni A, Amoroso D, Boni C, Gamucci T, Pinto C, Corsi D, D'Amico M, Bracarda S, Falcone A. Folfoxiri Plus Bevacizumab (Bv) or Plus Anti-Egfr Antibodies in Ras and Braf Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts): Analysis of Tumor Response. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Grande R, Pavese I, Natoli C, Ciancola F, Gemma D, Pellegrino A, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri E, Zampa G, Russano M, Gamucci T. Treatment (T) of Metastatic Colorectal Cancer (Mcrc) Patients (Pts) ≥75 Years (Y) Old in Clinical Practice: a Multicenter Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Mentuccia L, Vici P, Sperduti I, Pizzuti L, Moscetti L, Vaccaro A, Quadrini S, Magnolfi E, Fabbri M, Zampa G, Giampaolo M, Sergi D, Narducci F, Sacca MM, Gamucci T. Fact- B and Esas in Metastatic Breast Cancer (Mbc) Patients (Pts) Treated with Eribulin: Results of a Multicenter Prospective Observational Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu350.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, Passalacqua R, Iaffaioli V, Zilembo N, Mencoboni M, Roselli M, Pappagallo G, Pronzato P. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 2013; 31:797. [PMID: 24307348 DOI: 10.1007/s12032-013-0797-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 11/27/2013] [Indexed: 12/13/2022]
Abstract
Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥ 20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 10(9)/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.
Collapse
Affiliation(s)
- S Barni
- Oncology Department, Azienda Ospedaliera Treviglio, Treviglio, BG, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, Pavese I, Sperduti I, Vaccaro A, Vici P. Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. J Cancer Res Clin Oncol 2013; 140:221-6. [PMID: 24292401 PMCID: PMC3895217 DOI: 10.1007/s00432-013-1556-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Accepted: 11/18/2013] [Indexed: 01/05/2023]
Abstract
PURPOSE Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥ 2 diarrhea incidence and, secondarily, treatment efficacy. PATIENTS AND METHODS Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m(2), starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. RESULTS Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. CONCLUSION The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.
Collapse
Affiliation(s)
- T Gamucci
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100, Frosinone, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139:853-60. [PMID: 23411686 PMCID: PMC3625404 DOI: 10.1007/s00432-013-1388-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 01/29/2013] [Indexed: 01/03/2023]
Abstract
PURPOSE Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, accordingly with some prognostic biological factors. METHODS We retrospectively evaluated 900 node-negative patients (pT1a, b, c) surgery treated between 2000 and 2009 in four Italian oncologic centers. We defined 3 different cohorts: ER positive (ER+); Her-2 positive (Her-2+); and triple negative (TN). RESULTS pT1a was seen in 7.6% of patients, 37.7 % pT1b, 54.8 % pT1c. Concerning the 3 different cohorts, 58.2 % were ER+; 10.8 % were Her-2+; 8.2 % were TN. Overall, chemotherapy was given to 3.0 %, 27.2 %, 69.8 % of pT1a, b, c, respectively, and to 22.7 %, 58.8 %, 68.9 % of ER+, Her-2+, TN subgroups. At a median follow-up of 67 months, 5-year DFS was 96.3 %, 89.2 %, 89.4 % in pT1a, b, c, respectively (100 %, 93.6 %, 89.8 % in ER+; 100 %, 78.7 %, 85.0 % in Her-2+; 100 %, 76.8 %, 85.2 % in TN) (p = ns). At multivariate analysis, histologic grade and Ki-67 resulted independent prognostic factors. Overall, 5-year OS was 98 %, without differences among pT1a, b, c, or among the 3 cohorts. CONCLUSIONS Overall, 5-year DFS was very favorable in this series of small, node-negative breast cancers, but Her-2+ and TN cohorts have a higher recurrence rate than ER+ cohort (p < 0.0001); pT1c, but also pT1b, in Her-2+ and TN subgroups, have a worse outcome, and effective chemotherapy treatment should be considered in these unfavorable subgroups.
Collapse
Affiliation(s)
- T. Gamucci
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - A. Vaccaro
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - F. Ciancola
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Pizzuti
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - I. Sperduti
- Department of Biostatistics, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - L. Moscetti
- Medical Oncology Unit, Belcolle Hospital, Strada Sammartinese 1, 01100 Viterbo, Italy
| | - F. Longo
- Medical Oncology Unit A, La Sapienza University of Rome, Viale del Policlinico 161, 00161 Rome, Italy
| | - M. A. Fabbri
- Medical Oncology Unit, Belcolle Hospital, Strada Sammartinese 1, 01100 Viterbo, Italy
| | - M. A. Giampaolo
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Mentuccia
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Di Lauro
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - P. Vici
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| |
Collapse
|
40
|
Silvestris N, Leo S, Di Palma T, De Vita F, Gamucci T, Barni S, Ferrara R, Mazzara C, Numico G, Colucci G. Natural History of Bone Metastasis in Gastric Cancer: Results of an Italian Multicenter Survey. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33260-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
41
|
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva R, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:1436-41. [DOI: 10.1093/annonc/mdr474] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
42
|
Vaccaro A, Ciancola F, Vici P, Sperduti I, Moscetti L, Pizzuti L, Di Seri M, Ruggeri E, Giampaolo M, Gamucci T. 5187 POSTER Unfavourable Prognosis in PT1b HER2 Positive and Triple Negative Breast Cancer Patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71629-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Moscetti L, Cortesi E, Gamucci T, Sperduti I, Pavese I, Franco D, Alesini D, Fabbri A, Grande R, Gemma D, Signorelli C, Ruggeri E. Maintenance treatment with bevacizumab after chemotherapy (CT) plus B in metastatic colorectal cancer: An Italian multicenter retrospective analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Grande R, Narducci F, Mansueto G, Gemma D, Sperduti I, Bianchetti S, Angelini F, Trombetta G, Gamucci T. Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and limecicline—A phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Vici P, Longo F, Ruggeri E, Di Seri M, Giampaolo MA, Gamucci T. High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol 2011; 121:280-4. [PMID: 21277010 DOI: 10.1016/j.ygyno.2011.01.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 12/26/2010] [Accepted: 01/03/2011] [Indexed: 11/28/2022]
Abstract
OBJECTIVE Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for pure ovarian dysgerminoma (POD), except for correctly staged IA patients. The aim of study was to evaluate the outcome of IA POD patients with incomplete surgical staging in order to define the proper management. METHODS Data concerning primary treatment and recurrence were reviewed for 26 patients with stage IA POD treated in MITO (Multicenter Italian Trials in Ovarian Cancer) centers. RESULTS Median age was 22.5years. Primary surgery was fertility sparing for 17 patients (65.4%) and radical surgery was performed in 9 patients due to older age or gonadal dysgenesis. Only five patients (19.2%) had complete surgical staging; 38.5% had lymph node dissection, 46.2% had peritoneal biopsies and/or omentectomy and 65.4% had peritoneal washing. Seven patients received adjuvant chemotherapy. Overall recurrence rate was 11.5%: all recurrences occurred in the group submitted to incomplete staging procedure. No patients treated with adjuvant chemotherapy relapsed. One patient had pelvic recurrence, one patient relapsed in the abdomino-pelvic peritoneum and lymph nodes and the third patient showed a peritoneum, lymph nodal and residual ovary relapse. All patients with recurrence were cured by salvage therapy: 2 patients were treated with surgery plus chemotherapy and one only with chemotherapy. After a median follow-up of 100months all patients are alive without evidence of disease. Six patients opted for conception and delivered healthy infants, two with IVF with donor oocyte. CONCLUSIONS IA POD prognosis is excellent. Conservative surgery with a complete surgical staging is the gold standard. Patients with incomplete staging could undergo surgical restaging or surveillance. Chemotherapy should be reserved to relapse with excellent chances of therapeutic success.
Collapse
Affiliation(s)
- G Mangili
- Gynecology Department, I.R.C.C.S. San Raffaele Hospital, Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Musolino A, Bisagni G, De Matteis A, Nuzzo F, Ardizzoni A, Crinò L, Gamucci T, Passalacqua R, Gnoni R, Boni C. Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (B) has demonstrated efficacy with taxanes in the first-line setting. This study was conducted to assess the efficacy and safety of TX-B in patients (pts) with MBC. Patients and methods: In this single-arm, multicenter phase II study, pts received first-line bevacizumab 15 mg/kg and docetaxel 60 mg/m2 on day 1, plus capecitabine 900 mg/m2 twice per day on days 1-14 every 21 days. The treatment was administrated for 3 cycles and in case of objective response or stable disease at that time, pts were treated with 3 additional cycles. More courses of chemotherapy were administered at Investigator's discretion. Bevacizumab was continued until progressive disease, patient refusal, or unacceptable toxicity. Primary end point was progression-free survival (PFS) and secondary end points were tumor response rate (RR), overall survival (OS), and toxicity.
Results: We report data from the first 30 pts enrolled. Median age was 54 (37-72). Eight (27%) pts had triple-negative disease, while 18 (60%) were hormone-receptor positive. HER2 status was recognized as negative in 25 (84%) pts. TX-B was administered for a median of seven cycles. Five complete and 13 partial responses were observed (overall RR 60%). Median response duration was 12 months. Median OS and PFS were 26 and 11 months, respectively. Grade 3/4 adverse events included tromboembolism (10%), neutropenia (23%), hand-foot syndrome (13%), stomatitis (10%). The median TX doses administered per cycle were 60 mg/m2 and 660 mg/m2, respectively. Ten (33%) pts required dose reductions of docetaxel, while capecitabine dose was reduced in 15 (50%) pts. Results of all the 80 assessable pts entered in the study will be presented at the meeting.
Conclusion: TX-B demonstrated significant activity with an acceptable toxicity profile. Maintenance therapy with B is possible for a long period of stable tumor disease.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-17-01.
Collapse
Affiliation(s)
- A Musolino
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - G Bisagni
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - A De Matteis
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - F Nuzzo
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - A Ardizzoni
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - L Crinò
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - T Gamucci
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - R Passalacqua
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - R Gnoni
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| | - C. Boni
- University Hospital of Parma, Italy; Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Istituto Nazionale Tumori-Fondazione G. Pascale, Napoli, Italy; Ospedale S. Maria della Misericordia, Perugia, Italy; Ospedale Santissima Trinità, Frosinone, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Italian Oncology Group for Clinical Research (GOIRC), Italy
| |
Collapse
|
49
|
Grande R, Cianci G, Sperduti I, Gemma D, Gelibter A, Giampaolo M, Mentuccia L, Narducci F, Magnolfi E, Gamucci T. FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Milella M, Vaccaro V, Sperduti I, Bria E, Gelibter A, Mansueto G, Moscetti L, Gamucci T, Ruggeri E, Cognetti F. Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14565] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|